jodmicriice

  The global molecular point of care testing (using NAAT) market is expected to grow due to improving healthcare facilities and infrastructures and the adoption of end-of-care testing at the hospital, laboratories, and clinics, which can drive the market's growth. The other factors anticipated to propel the development of the molecular point of care testing (using NAAT) market include the rising prevalence of infectious diseases. POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting v...

  The other factors, such as the lack of skilled professionals and the high cost of customized molecular point-of-care testing (using NAAT), hamper the growth of the global molecular end-of-care testing (using NAAT) market. On the other hand, the increased healthcare expenditure and emerging countries with developed hospitals act as an opportunity to grow the global molecular point of care testing (using NAAT) market. POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting various disor...

  The other factors, such as the lack of skilled professionals and the high cost of customized molecular point-of-care testing (using NAAT), hamper the growth of the global molecular end-of-care testing (using NAAT) market. On the other hand, the increased healthcare expenditure and emerging countries with developed hospitals act as an opportunity to grow the global molecular point of care testing (using NAAT) market. POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting various disor...